The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Single-institution experience using bevacizumab for IDH1/2-mutant gliomas.
 
Collin Le
No Relationships to Disclose
 
Chuyin Yang
No Relationships to Disclose
 
Blaine Eldred
No Relationships to Disclose
 
Terry Prins
No Relationships to Disclose
 
Addison Fisher
No Relationships to Disclose
 
Tie Li
No Relationships to Disclose
 
Linda Liau
No Relationships to Disclose
 
Richard Everson
No Relationships to Disclose
 
Robert Chong
Consulting or Advisory Role - Anhart; SERVIER
Speakers' Bureau - SERVIER
 
Phioanh Leia Nghiemphu
Honoraria - Alexion Pharmaceuticals
Consulting or Advisory Role - SpringWorks Therapeutics
Research Funding - children's Tumor Foundation (Inst); Chimerix (Inst); Erasca, Inc (Inst); Global Coalition for Adaptive Research (Inst); Millennium (Inst); NCCN (Inst); Recursion Pharmaceuticals (Inst); SpringWorks Therapeutics (Inst)
 
Timothy Cloughesy
Leadership - Katmai Pharmaceuticals
Stock and Other Ownership Interests - Chimerix; Erasca, Inc; Katmai Pharmaceuticals
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Chimerix; DelMar Pharmaceuticals; Global Coalition for Adaptive Research; Inovio Pharmaceuticals; Katmai Pharmaceuticals; KIYATEC; Lista; Merck; Mundipharma; Novartis; QED Therapeutics; Roche/Genentech; Sapience Therapeutics; SERVIER; SonaCare Medical; SymBio Pharmaceuticals; Tango Therapeutics; Tocagen; VBL Therapeutics
Patents, Royalties, Other Intellectual Property - U.S. Provisional Application No.: 62/819,322 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Filing Date: March 15, 2019 Inventor(s): David A. Nathanson et al. FH Reference No.: UCH-17760 (32246-17760) Your Reference No.: [UCLA 2019-630-1] US
Other Relationship - Break Through Cancer; Global Coalition for Adaptive Research
 
Catalina Raymond
No Relationships to Disclose
 
Francesco Sanvito
No Relationships to Disclose
 
Benjamin Ellingson
Consulting or Advisory Role - Alpheus Medical; CarThera; Chimerix; Curtana; Ellipses Pharma; Global Coalition for Adaptive Research; Imaging Endpoints; ImmunoGenesis; Medicenna; Monteris Medical; Neosoma; Orbus Therapeutics; Sagimet Biosciences; Sapience Therapeutics; SERVIER; Siemens; Sumitomo Dainippon Pharma Oncology; Voiant/MedQIA
Research Funding - Siemens
Travel, Accommodations, Expenses - Siemens
 
Albert Lai
Consulting or Advisory Role - SERVIER